Trial Outcomes & Findings for Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma (NCT NCT02432235)

Last Updated: 2021-07-13

Results Overview

A DLT defined as any of the following, except those that are clearly due to underlying disease or extraneous causes: A hematologic DLT is defined as (different considerations for Adult T-Cell Leukemia/Lymphoma (ATLL) participants): * Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 febrile neutropenia or neutropenic infection * CTCAE Grade 4 neutropenia lasting \>7 days * CTCAE Grade 4 thrombocytopenia * CTCAE Grade 3 thrombocytopenia with clinically significant bleeding, or Grade 3 thrombocytopenia requiring a platelet transfusion * CTCAE Grade 4 anemia A non-hematologic DLT is defined as: * CTCAE Grade 4 tumor lysis syndrome * CTCAE Grade 3 or higher AE (including nausea, vomiting, diarrhea, electrolyte imbalances lasting ≥ 48 hours despite optimal therapy; excluding all grades of alopecia) * CTCAE Grade 3 or higher hypersensitivity reaction * CTCAE Grade 2 or higher skin ulceration * CTCAE Grade 2 or higher peripheral sensory or motor neuropathy

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

133 participants

Primary outcome timeframe

Cycle 1 Day 1 to end of Cycle 1 or 2 (21 day cycle length)

Results posted on

2021-07-13

Participant Flow

There were 12 sites that screened and enrolled participants: USA: 7 sites; UK: 5 sites.

Participants were included in a screening period of up to 28 days.

Participant milestones

Participant milestones
Measure	3 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	5 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	8 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	13 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	20 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	30 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	45 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	60 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	80 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	100 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	150 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	300 μg/kg A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles). Camidanlumab tesirine: Intravenous (IV) infusion.
Overall Study STARTED	2	2	2	3	2	20	41	29	26	3	2	1
Overall Study COMPLETED	1	0	0	1	0	8	23	9	5	0	1	0
Overall Study NOT COMPLETED	1	2	2	2	2	12	18	20	21	3	1	1

Reasons for withdrawal

Reasons for withdrawal
Measure	3 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	5 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	8 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	13 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	20 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	30 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	45 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	60 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	80 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	100 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	150 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	300 μg/kg A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles). Camidanlumab tesirine: Intravenous (IV) infusion.
Overall Study Death	1	1	2	2	1	3	11	15	15	3	1	0
Overall Study Withdrawal by Subject	0	1	0	0	0	2	5	3	1	0	0	0
Overall Study Lost to Follow-up	0	0	0	0	0	1	0	0	1	0	0	0
Overall Study Miscellaneous	0	0	0	0	1	6	2	2	4	0	0	1

Baseline Characteristics

One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	300 μg/kg n=1 Participants A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles). Camidanlumab tesirine: Intravenous (IV) infusion.	Total n=133 Participants Total of all reporting groups	3 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	5 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	8 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	13 μg/kg n=3 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	20 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	30 μg/kg n=20 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	45 μg/kg n=41 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	60 μg/kg n=29 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	80 μg/kg n=26 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	100 μg/kg n=3 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	150 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.
Age, Continuous	64.0 years n=1 Participants	50.8 years STANDARD_DEVIATION 17.13 • n=133 Participants	73.5 years STANDARD_DEVIATION 2.12 • n=2 Participants	44.0 years STANDARD_DEVIATION 2.83 • n=2 Participants	64.0 years STANDARD_DEVIATION 12.73 • n=2 Participants	51.0 years STANDARD_DEVIATION 12.53 • n=3 Participants	38.0 years STANDARD_DEVIATION 19.80 • n=2 Participants	42.1 years STANDARD_DEVIATION 16.32 • n=20 Participants	45.1 years STANDARD_DEVIATION 15.48 • n=41 Participants	56.3 years STANDARD_DEVIATION 18.16 • n=29 Participants	58.1 years STANDARD_DEVIATION 15.69 • n=26 Participants	58.7 years STANDARD_DEVIATION 8.08 • n=3 Participants	44.5 years STANDARD_DEVIATION 19.09 • n=2 Participants
Sex: Female, Male Female	1 Participants n=1 Participants	55 Participants n=133 Participants	1 Participants n=2 Participants	1 Participants n=2 Participants	1 Participants n=2 Participants	2 Participants n=3 Participants	1 Participants n=2 Participants	8 Participants n=20 Participants	14 Participants n=41 Participants	15 Participants n=29 Participants	10 Participants n=26 Participants	0 Participants n=3 Participants	1 Participants n=2 Participants
Sex: Female, Male Male	0 Participants n=1 Participants	78 Participants n=133 Participants	1 Participants n=2 Participants	1 Participants n=2 Participants	1 Participants n=2 Participants	1 Participants n=3 Participants	1 Participants n=2 Participants	12 Participants n=20 Participants	27 Participants n=41 Participants	14 Participants n=29 Participants	16 Participants n=26 Participants	3 Participants n=3 Participants	1 Participants n=2 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=1 Participants	13 Participants n=133 Participants	0 Participants n=2 Participants	1 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants	2 Participants n=20 Participants	5 Participants n=41 Participants	3 Participants n=29 Participants	2 Participants n=26 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	1 Participants n=1 Participants	120 Participants n=133 Participants	2 Participants n=2 Participants	1 Participants n=2 Participants	2 Participants n=2 Participants	3 Participants n=3 Participants	2 Participants n=2 Participants	18 Participants n=20 Participants	36 Participants n=41 Participants	26 Participants n=29 Participants	24 Participants n=26 Participants	3 Participants n=3 Participants	2 Participants n=2 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=1 Participants	0 Participants n=133 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants	0 Participants n=20 Participants	0 Participants n=41 Participants	0 Participants n=29 Participants	0 Participants n=26 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=1 Participants	0 Participants n=133 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants	0 Participants n=20 Participants	0 Participants n=41 Participants	0 Participants n=29 Participants	0 Participants n=26 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants
Race (NIH/OMB) Asian	0 Participants n=1 Participants	4 Participants n=133 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	1 Participants n=3 Participants	0 Participants n=2 Participants	0 Participants n=20 Participants	2 Participants n=41 Participants	0 Participants n=29 Participants	0 Participants n=26 Participants	1 Participants n=3 Participants	0 Participants n=2 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=1 Participants	0 Participants n=133 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants	0 Participants n=20 Participants	0 Participants n=41 Participants	0 Participants n=29 Participants	0 Participants n=26 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants
Race (NIH/OMB) Black or African American	0 Participants n=1 Participants	17 Participants n=133 Participants	1 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	1 Participants n=3 Participants	0 Participants n=2 Participants	0 Participants n=20 Participants	5 Participants n=41 Participants	1 Participants n=29 Participants	9 Participants n=26 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants
Race (NIH/OMB) White	1 Participants n=1 Participants	106 Participants n=133 Participants	1 Participants n=2 Participants	2 Participants n=2 Participants	2 Participants n=2 Participants	1 Participants n=3 Participants	1 Participants n=2 Participants	19 Participants n=20 Participants	30 Participants n=41 Participants	28 Participants n=29 Participants	17 Participants n=26 Participants	2 Participants n=3 Participants	2 Participants n=2 Participants
Race (NIH/OMB) More than one race	0 Participants n=1 Participants	0 Participants n=133 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants	0 Participants n=20 Participants	0 Participants n=41 Participants	0 Participants n=29 Participants	0 Participants n=26 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=1 Participants	6 Participants n=133 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=3 Participants	1 Participants n=2 Participants	1 Participants n=20 Participants	4 Participants n=41 Participants	0 Participants n=29 Participants	0 Participants n=26 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants
Region of Enrollment United States	1 participants n=1 Participants	98 participants n=133 Participants	2 participants n=2 Participants	2 participants n=2 Participants	2 participants n=2 Participants	3 participants n=3 Participants	2 participants n=2 Participants	20 participants n=20 Participants	27 participants n=41 Participants	20 participants n=29 Participants	16 participants n=26 Participants	2 participants n=3 Participants	1 participants n=2 Participants
Region of Enrollment United Kingdom	0 participants n=1 Participants	35 participants n=133 Participants	0 participants n=2 Participants	0 participants n=2 Participants	0 participants n=2 Participants	0 participants n=3 Participants	0 participants n=2 Participants	0 participants n=20 Participants	14 participants n=41 Participants	9 participants n=29 Participants	10 participants n=26 Participants	1 participants n=3 Participants	1 participants n=2 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status Grade 0	0 Participants n=1 Participants	43 Participants n=133 Participants	0 Participants n=2 Participants	1 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants	6 Participants n=20 Participants	16 Participants n=41 Participants	12 Participants n=29 Participants	7 Participants n=26 Participants	0 Participants n=3 Participants	1 Participants n=2 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status Grade 1	1 Participants n=1 Participants	79 Participants n=133 Participants	2 Participants n=2 Participants	0 Participants n=2 Participants	2 Participants n=2 Participants	1 Participants n=3 Participants	2 Participants n=2 Participants	14 Participants n=20 Participants	24 Participants n=41 Participants	13 Participants n=29 Participants	16 Participants n=26 Participants	3 Participants n=3 Participants	1 Participants n=2 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status Grade 2	0 Participants n=1 Participants	11 Participants n=133 Participants	0 Participants n=2 Participants	1 Participants n=2 Participants	0 Participants n=2 Participants	2 Participants n=3 Participants	0 Participants n=2 Participants	0 Participants n=20 Participants	1 Participants n=41 Participants	4 Participants n=29 Participants	3 Participants n=26 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status Grade 3	0 Participants n=1 Participants	0 Participants n=133 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants	0 Participants n=20 Participants	0 Participants n=41 Participants	0 Participants n=29 Participants	0 Participants n=26 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status Grade 4	0 Participants n=1 Participants	0 Participants n=133 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants	0 Participants n=20 Participants	0 Participants n=41 Participants	0 Participants n=29 Participants	0 Participants n=26 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status Grade 5	0 Participants n=1 Participants	0 Participants n=133 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants	0 Participants n=20 Participants	0 Participants n=41 Participants	0 Participants n=29 Participants	0 Participants n=26 Participants	0 Participants n=3 Participants	0 Participants n=2 Participants
Weight	53.20 kilograms (kg) n=1 Participants	80.69 kilograms (kg) STANDARD_DEVIATION 23.766 • n=133 Participants	98.05 kilograms (kg) STANDARD_DEVIATION 26.517 • n=2 Participants	55.25 kilograms (kg) STANDARD_DEVIATION 12.799 • n=2 Participants	80.40 kilograms (kg) STANDARD_DEVIATION 19.658 • n=2 Participants	63.57 kilograms (kg) STANDARD_DEVIATION 4.840 • n=3 Participants	65.05 kilograms (kg) STANDARD_DEVIATION 14.496 • n=2 Participants	79.18 kilograms (kg) STANDARD_DEVIATION 19.920 • n=20 Participants	89.10 kilograms (kg) STANDARD_DEVIATION 31.926 • n=41 Participants	75.15 kilograms (kg) STANDARD_DEVIATION 18.241 • n=29 Participants	78.19 kilograms (kg) STANDARD_DEVIATION 15.780 • n=26 Participants	82.67 kilograms (kg) STANDARD_DEVIATION 15.808 • n=3 Participants	96.50 kilograms (kg) STANDARD_DEVIATION 12.869 • n=2 Participants
Height	155.00 centimeters (cm) n=1 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.	171.37 centimeters (cm) STANDARD_DEVIATION 9.920 • n=129 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.	176.65 centimeters (cm) STANDARD_DEVIATION 24.961 • n=2 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.	158.00 centimeters (cm) STANDARD_DEVIATION 1.414 • n=2 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.	176.00 centimeters (cm) STANDARD_DEVIATION 4.243 • n=2 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.	170.43 centimeters (cm) STANDARD_DEVIATION 5.811 • n=3 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.	170.20 centimeters (cm) n=1 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.	172.13 centimeters (cm) STANDARD_DEVIATION 11.212 • n=19 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.	172.12 centimeters (cm) STANDARD_DEVIATION 9.410 • n=39 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.	171.43 centimeters (cm) STANDARD_DEVIATION 9.341 • n=29 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.	170.33 centimeters (cm) STANDARD_DEVIATION 10.188 • n=26 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.	173.43 centimeters (cm) STANDARD_DEVIATION 10.856 • n=3 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.	172.50 centimeters (cm) STANDARD_DEVIATION 13.435 • n=2 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken.
Body Mass Index	22.14 kg/m^2 n=1 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken, and so their Body Mass Index could not be calculated.	27.52 kg/m^2 STANDARD_DEVIATION 7.757 • n=129 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken, and so their Body Mass Index could not be calculated.	33.60 kg/m^2 STANDARD_DEVIATION 17.816 • n=2 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken, and so their Body Mass Index could not be calculated.	22.18 kg/m^2 STANDARD_DEVIATION 5.524 • n=2 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken, and so their Body Mass Index could not be calculated.	25.83 kg/m^2 STANDARD_DEVIATION 5.100 • n=2 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken, and so their Body Mass Index could not be calculated.	21.98 kg/m^2 STANDARD_DEVIATION 2.829 • n=3 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken, and so their Body Mass Index could not be calculated.	25.99 kg/m^2 n=1 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken, and so their Body Mass Index could not be calculated.	26.69 kg/m^2 STANDARD_DEVIATION 4.496 • n=19 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken, and so their Body Mass Index could not be calculated.	30.26 kg/m^2 STANDARD_DEVIATION 11.193 • n=39 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken, and so their Body Mass Index could not be calculated.	25.37 kg/m^2 STANDARD_DEVIATION 4.913 • n=29 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken, and so their Body Mass Index could not be calculated.	26.95 kg/m^2 STANDARD_DEVIATION 4.944 • n=26 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken, and so their Body Mass Index could not be calculated.	27.47 kg/m^2 STANDARD_DEVIATION 4.559 • n=3 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken, and so their Body Mass Index could not be calculated.	33.07 kg/m^2 STANDARD_DEVIATION 9.447 • n=2 Participants • One participant in the 20 μg/kg group, one participant in the 30 μg/kg group and two participants in the 45 μg/kg group did not have their height measurement taken, and so their Body Mass Index could not be calculated.

PRIMARY outcome

Timeframe: Cycle 1 Day 1 to end of Cycle 1 or 2 (21 day cycle length)

Population: DLT Evaluable Analysis Set: The DLT-evaluable analysis set consisted of participants who completed two cycles of ADCT-301 if enrolled prior to protocol amendment 4 and participants who completed one cycle of ADCT-301 if enrolled after protocol amendment 4. The participants with completed DLT information were included even if they discontinued early before the end of cycle 2 or cycle 1 respectively.

Outcome measures

Outcome measures
Measure	3 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	5 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	8 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	13 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	20 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	30 μg/kg n=10 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	45 μg/kg n=15 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	60 μg/kg n=29 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	80 μg/kg n=16 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	100 μg/kg n=3 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	150 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	300 μg/kg n=1 Participants A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles). Camidanlumab tesirine: Intravenous (IV) infusion.
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	2 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Cycle 1 Day 1 to end of Cycle 1 or 2 (21 day cycle length)

Population: Number of participants analyzed presented in the outcome measure data are only those participants in the DLT evaluable analysis set who were dosed at the three dose levels recommended for Part 2.

The recommended dose was established by the dose escalation steering committee and based on safety findings during Part 1 of the study.

Outcome measures

Outcome measures
Measure	3 μg/kg n=86 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	5 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	8 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	13 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	20 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	30 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	45 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	60 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	80 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	100 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	150 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	300 μg/kg A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles). Camidanlumab tesirine: Intravenous (IV) infusion.
Recommended Dose of Camidanlumab Tesirine for Part 2 Participants with Hodgkin Lymphoma (Dose level 1: 30 µg/kg)	30 μg/kg	—	—	—	—	—	—	—	—	—	—	—
Recommended Dose of Camidanlumab Tesirine for Part 2 Participants with Hodgkin Lymphoma (Dose level 2: 45 µg/kg)	45 μg/kg	—	—	—	—	—	—	—	—	—	—	—
Recommended Dose of Camidanlumab Tesirine for Part 2 Participants with T-cell Lymphoma (80 µg/kg)	80 μg/kg	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1 up to 84 days after last dose (median time on treatment was 43 days [min 1 day; max 354 days])

An adverse event (AE) is defined as any untoward medical occurrence in a participant enrolled into this study regardless of its causal relationship to study drug. A TEAE is defined as any event not present before exposure to study drug or any event already present that worsens in either intensity or frequency after exposure to study drug.

Outcome measures

Outcome measures
Measure	3 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	5 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	8 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	13 μg/kg n=3 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	20 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	30 μg/kg n=20 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	45 μg/kg n=41 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	60 μg/kg n=29 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	80 μg/kg n=26 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	100 μg/kg n=3 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	150 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	300 μg/kg n=1 Participants A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles). Camidanlumab tesirine: Intravenous (IV) infusion.
Number of Participants Reporting at Least One Treatment Emergent Adverse Event (TEAE)	1 Participants	2 Participants	2 Participants	3 Participants	2 Participants	20 Participants	41 Participants	29 Participants	26 Participants	3 Participants	2 Participants	1 Participants

PRIMARY outcome

Timeframe: Day 1 up to 84 days after last dose (median time on treatment was 43 days [min 1 day; max 354 days])

A treatment-emergent AE (TEAE) is defined as any event not present before exposure to study drug or any event already present that worsens in either intensity or frequency after exposure to study drug. An SAE is defined as any event that results in death, is immediately life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

Outcome measures

Outcome measures
Measure	3 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	5 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	8 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	13 μg/kg n=3 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	20 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	30 μg/kg n=20 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	45 μg/kg n=41 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	60 μg/kg n=29 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	80 μg/kg n=26 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	100 μg/kg n=3 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	150 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	300 μg/kg n=1 Participants A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles). Camidanlumab tesirine: Intravenous (IV) infusion.
Number of Participants Reporting at Least One Treatment Emergent Serious Adverse Event (SAE)	0 Participants	1 Participants	0 Participants	3 Participants	1 Participants	10 Participants	24 Participants	14 Participants	18 Participants	1 Participants	1 Participants	1 Participants

SECONDARY outcome

Timeframe: Day 1 to End of Study (a maximum of 12 months after treatment; median time on treatment was 43 days [min 1 day; max 354 days])

Population: Efficacy Analysis Set: The efficacy analysis set consisted of participants who received at least one dose of camidanlumab tesirine with a valid baseline and at least one valid post-baseline disease assessment or participants who had documented progression of disease or death at any time after the first dose of study.

ORR is defined as the number of participants with a best overall response of complete response (CR) or partial response (PR) at the time each participant discontinued treatment with camidanlumab tesirine. Tumor response was assessed using the 2014 Lugano Classification. CR is defined as achieving each of the following: * Complete metabolic response. * Complete radiologic response (target node regress to \<1.5 cm, no nonmeasured lesions, no organ enlargement, no new lesions and normal bone marrow morphology). PR is defined as achieving each of the following: * Partial metabolic response (findings indicate residual disease). * Partial remission (\>50% decrease in target measurable nodes, regression/ absence/ no increase of nonmeasured lesions, spleen regressed by \>50% in length and no new lesions).

Outcome measures

Outcome measures
Measure	3 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	5 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	8 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	13 μg/kg n=3 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	20 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	30 μg/kg n=20 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	45 μg/kg n=41 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	60 μg/kg n=28 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	80 μg/kg n=24 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	100 μg/kg n=3 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	150 μg/kg n=2 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	300 μg/kg n=1 Participants A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles). Camidanlumab tesirine: Intravenous (IV) infusion.
Overall Response Rate (ORR)	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	11 Participants	32 Participants	15 Participants	12 Participants	2 Participants	1 Participants	1 Participants

SECONDARY outcome

Timeframe: Day 1 to End of Study (a maximum of 12 months after last dose; median time on treatment was 43 days [min 1 day; max 354 days])

DoR is defined among responders (complete response \[CR\] and partial response \[PR\]) as the time from the earliest date of first response until the first date of either disease progression or death due to any cause. Tumor response was assessed using the 2014 Lugano Classification. Disease progression is defined as progressive metabolic disease and one of the follow: * Target node progression. * An individual extranodal lesion must be abnormal with length \> 1.5cm and/or increase of length \> 50%. * New or clear progression of nonmeasured lesions. * Regrowth of previously resolved lesions or new nodes \>1.5 cm in length. * New or recurrent bone marrow involvement. DoR is presented overall for all participants who were classed as responders among the efficacy analysis set. Data is pooled for all lymphoma participants for DoR as specified in protocol section 8.4.

Outcome measures

Outcome measures
Measure	3 μg/kg n=130 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	5 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	8 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	13 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	20 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	30 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	45 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	60 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	80 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	100 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	150 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	300 μg/kg A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles). Camidanlumab tesirine: Intravenous (IV) infusion.
Duration of Response (DoR)	5.19 Months Interval 4.5 to 7.23	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 to End of Study (a maximum of 12 months after last dose; median time on treatment was 43 days [min 1 day; max 354 days])

Progression-free survival (PFS) is defined among the efficacy population as the time from first dose of study drug until either disease progression or death due to any cause. Tumor response was assessed using the 2014 Lugano Classification for response. Disease progression is defined as progressive metabolic disease and one of the following: * Target node progression. * An individual extranodal lesion must be abnormal with length \> 1.5cm and/or increase of length \> 50%. * New or clear progression of nonmeasured lesions. * Regrowth of previously resolved lesions or new nodes \> 1.5 cm in length. * New or recurrent bone marrow involvement. PFS is presented overall for all participants who received camidanlumab tesirine among the efficacy analysis set. Data is pooled for all lymphoma participants for PFS as specified in protocol section 8.4

Outcome measures

Outcome measures
Measure	3 μg/kg n=130 Participants Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	5 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	8 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	13 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	20 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	30 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	45 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	60 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	80 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	100 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	150 μg/kg Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles. Camidanlumab tesirine: Intravenous (IV) infusion.	300 μg/kg A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles). Camidanlumab tesirine: Intravenous (IV) infusion.
Progression-Free Survival (PFS)	5.22 Months Interval 3.78 to 5.95	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 to End of Study (a maximum of 12 months after last dose; median time on treatment was 43 days [min 1 day; max 354 days])

Overall survival (OS) is defined as the time from the first dose of study drug treatment until the date of death due to any cause. OS is presented overall for all participants who received camidanlumab tesirine among the efficacy analysis set. Data is pooled for all lymphoma participants for OS as specified in protocol section 8.4.